RCT | Induction therapy with olamkicept vs. placebo in patients with active ulcerative colitis
13 Mar, 2023 | 14:48h | UTCEffect of Induction Therapy With Olamkicept vs Placebo on Clinical Response in Patients With Active Ulcerative Colitis: A Randomized Clinical Trial – JAMA (free for a limited period)
Commentary on Twitter
Among patients with active ulcerative colitis, biweekly infusion of olamkicept 600 mg, but not 300 mg, resulted in a greater likelihood of clinical response at 12 weeks compared with placebo. https://t.co/I9h3jTZxlL pic.twitter.com/hgMvFhdzDa
— JAMA (@JAMA_current) March 8, 2023